Delay of Publication. Prior to the expiration of the thirty (30) day period specified in this Section 2.5, the Development Committee may notify the submitting party of its determination that such oral presentation or manuscript contains objectionable material or material that consists of patentable subject matter for which patent protection should be sought. The notified party shall withhold its proposed public disclosure and confer with the Development Committee to determine the best course of action to take in order to modify the disclosure or to obtain patent protection. After resolution of the regulatory or commercial issues, or the filing of a patent application or due consideration as to whether a patent application can reasonably be filed, the submitting party shall be free to submit the manuscript and/or make its public oral disclosure. If the submitting party declines to file an appropriate patent application pursuant to the request of the Development Committee, then either Introgen or RPRP may undertake to file such application in accordance with Article 14 below.
Appears in 2 contracts
Samples: Collaboration Agreement (Introgen Therapeutics Inc), Collaboration Agreement (Introgen Therapeutics Inc)
Delay of Publication. Prior to the expiration of the thirty (30) day period specified in this Section 2.55.2 above, the Development Committee other party may notify the submitting party in writing of its determination that such oral presentation or manuscript contains objectionable confidential or proprietary material of such other party or material that consists of patentable subject matter for which patent protection should be sought. The notified party shall withhold its proposed public disclosure and confer with the Development Committee other party to determine the best course of action to take in order to modify the disclosure or to obtain patent protection. After resolution of the confidentiality, regulatory or commercial other issues, or the filing of a patent application or due consideration as to whether a patent application can reasonably be filed, but in no event more than sixty (60) days after the submitting party's receipt of the notice described above, the submitting party shall be free to submit the manuscript and/or make its public oral disclosure. If the submitting party declines , subject to file an appropriate patent application pursuant to the request of the Development Committee, then either Introgen or RPRP may undertake to file such application in accordance with Article 14 16 below.
Appears in 2 contracts
Samples: Development and Commercialization Agreement (Neurocrine Biosciences Inc), Development and Commercialization Agreement (Neurocrine Biosciences Inc)